Growth hormone and bone

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 6, 2009, Pages 415-422

  Tritos, Nicholas A ^a,b   Biller, Beverly M K ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bone mineral density; Growth hormone; Growth hormone deficiency; Growth hormone replacement; Osteoporosis

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; GROWTH HORMONE; INSULIN RECEPTOR; PARATHYROID HORMONE; PLACEBO; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

BONE; BONE DENSITY; BONE MASS; BONE TURNOVER; CLINICAL TRIAL; FRACTURE; GROWTH; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; OSTEOPOROSIS; PRADER WILLI SYNDROME; PROTEIN EXPRESSION; REVIEW; RISK FACTOR;

ANIMALS; BONE AND BONES; BONE DENSITY; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MALE;

EID: 70350752357     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283319e6d     Document Type: Review

References (79)

1. Goeddel DV, Heyneker HL, Hozumi T, et al. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature 1979; 281:544-548.
2. Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep 1998; 21:553-566.
3. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
4. Mayo KE, Miller T, DeAlmeida V, et al. Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog Horm Res 2000; 55:237-266; discussion 266-267.
5. Yamashita S, Melmed S. Insulin-like growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells. J Clin Invest 1987; 79:449-452. (Pubitemid 17009678)
6. Leung DW, Spencer SA, Cachianes G, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987; 330:537-543.
7. Parker EA, Hegde A, Buckley M, et al. Spatial and temporal regulation of GHIGF- related gene expression in growth plate cartilage. J Endocrinol 2007; 194:31-40.
8. Harris WH, Heaney RP. Effect of growth hormone on skeletal mass in adult dogs. Nature 1969; 223:403-404.
9. Watson P, Lazowski D, Han V, et al. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone 1995; 16:357-365.
10. Bikle DD, Sakata T, Leary C, et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 2002; 17:1570-1578.
11. Ohlsson C, Nilsson A, Isaksson OG, Lindahl A. Effect of growth hormone and insulin-like growth factor-I on DNA synthesis and matrix production in rat epiphyseal chondrocytes in monolayer culture. J Endocrinol 1992; 133:291-300.
12. Hutchison MR, Bassett MH, White PC. Insulin-like growth factor-I and fibroblast growth factor, but not growth hormone, affect growth plate chondrocyte proliferation. Endocrinology 2007; 148:3122-3130.
13. Lupu F, Terwilliger JD, Lee K, et al. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001; 229:141-162.
14. Sims NA, Clement-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest 2000; 106:1095-1103.
15. Zhao G, Monier-Faugere MC, Langub MC, et al. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: Increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 2000; 141:2674-2682.
16. Zhang M, Xuan S, Bouxsein ML, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002; 277:44005-44012.
17. Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency. J Pediatr Endocrinol Metab 2003; 16 (Suppl 2):327-335.
18. Koranyi J, Svensson J, Gotherstrom G, et al. Baseline characteristics and the effects of five years ofGHreplacement therapy in adults with GHdeficiency of childhood or adulthood onset: A comparative, prospective study. J Clin Endocrinol Metab 2001; 86:4693-4699.
19. Murray RD, Columb B, Adams JE, Shalet SM. Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab 2004; 89:1124-1130.
20. Colao A, Di Somma C, Pivonello R, et al. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 1999; 84:1919-1924.
21. Hitz MF, Jensen JE, Eskildsen PC. Bone mineral density in patients with growth hormone deficiency: Does a gender difference exist? Clin Endocrinol (Oxf) 2006; 65:783-791.
22. Mazziotti G, Bianchi A, Cimino V, et al. Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. Pituitary 2008; 11:55-61.
23. Wuster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001; 16:398-405.
24. Mazziotti G, Bianchi A, Bonadonna S, et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: Influence of GH replacement therapy. J Bone Miner Res 2006; 21:520-528.
25. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, et al. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997; 137:240-245.
26. Abs R, Mattsson AF, Bengtsson BA, et al. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database. Growth Horm IGF Res 2005; 15:349-359.
27. White HD, Ahmad AM, Durham BH, et al. PTH circadian rhythm and PTH target-organ sensitivity is altered in patients with adult growth hormone deficiency with low BMD. J Bone Miner Res 2007; 22:1798-1807.
28. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958; 18:901-903.
29. Mauras N, Gonzalez de Pijem L, Hsiang HY, et al. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: A randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008; 93:823-831.
30. Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adultonset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996; 125:883-890.
31. Hansen TB, Brixen K, Vahl N, et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: A double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab 1996; 81:3352-3359.
32. Klefter O, Feldt-Rasmussen U. Is increase in bone mineral content caused by increase in skeletal muscle mass/strength in adult patients with growth hormone (GH) treated GH deficiency? A systematic literature analysis. Eur J Endocrinol 2009; 161:213-221.
33. Biller BM, Sesmilo G, Baum HB, et al. Withdrawal of long-term physiological growth hormone (GH) administration: Differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab 2000; 85:970-976.
34. Arwert LI, Roos JC, Lips P, et al. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin Endocrinol (Oxf) 2005; 63:310-316.
35. Bex M, Abs R, Maiter D, et al. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: A 2-year open randomized controlled multicenter trial. J Bone Miner Res 2002; 17:1081-1094.
36. Biermasz NR, Hamdy NA, Pereira AM, et al. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: A seven-year follow-up study. Clin Endocrinol (Oxf) 2004; 60:568-575.
37. Bravenboer N, Holzmann PJ, ter Maaten JC, et al. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormonedeficient men. J Bone Miner Res 2005; 20:1778-1784.
38. Drake WM, Rodriguez-Arnao J, Weaver JU, et al. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: A 5-year study. Clin Endocrinol (Oxf) 2001; 54:525-532.
39. Fideleff HL, Boquete HR, Stalldecker G, et al. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients. Growth Horm IGF Res 2008; 18:318-324.
40. Gotherstrom G, Bengtsson BA, Bosaeus I, et al. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol 2007; 156:55-64.
41. Hubina E, Lakatos P, Kovacs L, et al. Effects of 24 months of growth hormone (GH) treatment on serum carboxylated and undercarboxylated osteocalcin levels in GH-deficient adults. Calcif Tissue Int 2004; 74:55-59.
42. Rahim A, Holmes SJ, Adams JE, Shalet SM. Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy. Clin Endocrinol (Oxf) 1998; 48:463-469.
43. Snyder PJ, Biller BM, Zagar A, et al. Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency. J Bone Miner Res 2007; 22:762-770.
44. Rota F, Savanelli MC, Tauchmanova L, et al. Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender. J Endocrinol Invest 2008; 31:94-102.
45. de Paula FJ, Gois-Junior MB, Aguiar-Oliveira MH, et al. Consequences of lifetime isolated growth hormone (GH) deficiency and effects of short-term GH treatment on bone in adults with a mutation in the GHRH-receptor gene. Clin Endocrinol (Oxf) 2009; 70:35-40.
46. Norrman LL, Johannsson G, Sunnerhagen KS, Svensson J. Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly. J Clin Endocrinol Metab 2008; 93:2531-2538.
47. Shalet SM, Shavrikova E, Cromer M, et al. Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: A 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab 2003; 88:4124-4129.
48. Underwood LE, Attie KM, Baptista J. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: A two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 2003; 88:5273-5280.
49. Mauras N, Pescovitz OH, Allada V, et al. Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: A phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab 2005; 90:3946-3955.
50. Conway G, Szarras-Czapnik M, Racz K, et al. Treatment for 24 months with recombinant human growth hormone has a beneficial effect on bone mineral density in young adults with childhood-onset growth hormone deficiency. Eur J Endocrinol 2009; 160:899-907.
51. Nguyen VT, Misra M. Transitioning of children with GH deficiency to adult dosing: Changes in body composition. Pituitary 2009; 12:125-135.
52. Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: A statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007; 157:695-700.
53. van der Klaauw AA, van der Straaten T, Baak-Pablo R, et al. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. J Clin Endocrinol Metab 2008; 93:2828-2834.
54. Meyer S, Schaefer S, Ivan D, et al. Growth hormone dose in growth hormonedeficient adults is not associated with IGF-1 gene polymorphisms. Pharmacogenomics 2009; 10:293-302.
55. Meyer S, Haist M, Schaefer S, et al. Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GHdeficient adults. Pharmacogenomics 2008; 9:1017-1026.
56. Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: A randomized controlled trial. J Clin Endocrinol Metab 2001; 86:3079-3085.
57. Vestergaard P, Jorgensen JO, Hagen C, et al. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas: A case-control study. Clin Endocrinol (Oxf) 2002; 56:159-167.
58. Holmer H, Svensson J, Rylander L, et al. Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J Bone Miner Res 2007; 22:1842-1850.
59. Davenport ML, Crowe BJ, Travers SH, et al. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: A randomized, controlled, multicenter trial. J Clin Endocrinol Metab 2007; 92:3406-3416.
60. Aycan Z, Cetinkaya E, Darendeliler F, et al. The effect of growth hormone treatment on bone mineral density in prepubertal girls with Turner syndrome: A multicentre prospective clinical trial. Clin Endocrinol (Oxf) 2008; 68:769-772.
61. Willemsen RH, Arends NJ, Bakker-van Waarde WM, et al. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: Six-year follow-up of a randomized controlled GH trial. Clin Endocrinol (Oxf) 2007; 67:485-492.
62. Argente J, Gracia R, Ibanez L, et al. Improvement in growth after two years of growth hormone therapy in very young children born small for gestational age and without spontaneous catch-up growth: Results of a multicenter, controlled, randomized, open clinical trial. J Clin Endocrinol Metab 2007; 92:3095-3101.
63. Kemp SF, Kuntze J, Attie KM, et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab 2005; 90:5247-5253.
64. Moore WV, Dana K, Frane J, Lippe B. Growth hormone responsiveness: peak stimulated growth hormone levels and other variables in idiopathic short stature (ISS) - data from the National Cooperative Growth Study. Pediatr Endocrinol Rev 2008; 6:5-8.
65. Blum WF, Cao D, Hesse V, et al. Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome. Horm Res 2009; 71:167-172.
66. Romano AA, Dana K, Bakker B, et al. Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone. J Clin Endocrinol Metab 2009; 94:2338-2344.
67. Eiholzer U, Meinhardt U, Gallo C, et al. Association between foot growth and musculoskeletal loading in children with Prader-Willi syndrome before and during growth hormone treatment. J Pediatr 2009; 154:225-229.
68. de Lind van Wijngaarden RF, de Klerk LW, Festen DA, et al. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2009; 94:1274-1280.
69. Bechtold S, Ripperger P, Dalla Pozza R, et al. Growth hormone increases final height in patients with juvenile idiopathic arthritis: Data from a randomized controlled study. J Clin Endocrinol Metab 2007; 92:3013-3018.
70. Simon D, Prieur AM, Quartier P, et al. Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: A 3-year randomized study. J Clin Endocrinol Metab 2007; 92:2567-2573.
71. Polgreen LE, Plog M, Schwender JD, et al. Short-term growth hormone treatment in children with Hurler syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2009 [Epub ahead of print].
72. Geffner ME, Karlsson H. Use of recombinant human growth hormone in children with thalassemia. Horm Res 2009; 71 (Suppl 1):46-50.
73. Makitie O, Toiviainen-Salo S, Marttinen E, et al. Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets. Horm Res 2008; 69:212-220.
74. Dennison EM, Hindmarsh PC, Kellingray S, et al. Growth hormone predicts bone density in elderly women. Bone 2003; 32:434-440.
75. Joseph F, Ahmad AM, Ul-Haq M, et al. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. J Bone Miner Res 2008; 23:721-729.
76. Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA. Growth hormone increases bone mineral content in postmenopausal osteoporosis: A randomized placebo-controlled trial. J Bone Miner Res 2003; 18:393-405.
77. Sugimoto T, Kaji H, Nakaoka D, et al. Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis. Eur J Endocrinol 2002; 147:339-348.
78. Gillberg P, Mallmin H, Petren-Mallmin M, et al. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab 2002; 87:4900-4906.
79. Liu H, Bravata DM, Olkin I, et al. Systematic review: The safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007; 146:104-115.